Given the initial reports on the cytotoxic activity of TXNRD1 inhibitors, auranofin and TRi-1, on a range of cancer models through elevated ROS levels [12], we sought to test an underlying hypothesis in the field [8] (Figure 1A) and determine if similar results could be obtained with the B16F10 cell line (directly from the ATCC), a widely used cancer model for immunogenic metastatic melanoma. Here, TXNRD1 is linked to metastatic melanoma.